'Beyond Structure, Predicting
Function'
SHANGHAI, Dec. 25,
2024 /PRNewswire/ -- Recently, Shanghai Matwings
Technology Co., Ltd. ('Matwings'), a global leader in AI-driven
protein design, announced the successful completion of Series A
funding rounds, raising tens of millions of USD, led by Qiming
Venture Partners.
Matwings is pioneering a new frontier in protein engineering
with its proprietary AI-based general protein design platform,
AccelProtein™, which directly predicts protein functionality beyond
the structural data. By predicting functionality, AccelProtein™
offers a new approach for acquiring high-functioning proteins.
AccelProtein™ is built on the Pro-PRIME model, a breakthrough
developed by a collaborative team led by Professor Liang Hong at Shanghai Jiao Tong University.
After years of research focused on data collection, curation, and
optimization, the team developed the Pro-series - an AI framework
for protein design. Their work, titled "A General
Temperature-Guided Language Model to Design Proteins of Enhanced
Stability and Activity" was recently published in
Science Advances.
A featured case of AccelProtein™'s impact is the design of a
specialized Glycosyltransferase enzyme, which is used in the
production of EPS-G7, a core material for pancreatitis screening.
Within just 4 months, Matwings increased the enzyme's total
glycosylation activity by 7 times, enhanced product specificity
from 60% to 98%, and reduced hydrolytic activity by 33%. These
improvements cut down the cost of EPS-G7 by 90%.
In another application, Matwings successfully engineered a super
alkali-resistant affinity ligand (a nanobody) for affinity
chromatography, improving alkali resistance by 3 folds, binding
capacity over 100%, and heat stability by 8℃. This innovation saved
millions of USD in CMC costs for a Matwings client. Additionally,
scale-up production to 5000L has been successfully completed. Such
advancement enables low-cost affinity chromatography purification a
viable option for a wide range of biologics, bringing more
cost-effective solutions for drug production.
Since 2021, Matwings has successfully delivered over 30
protein-engineering and enzyme-mining projects either proprietary
(e.g., Enterokinase, Carboxypeptidase B, KEX2 Protease, Maltogenic
Amylase, Subtilisin, Protein A, PETase, T7 RNA Polymerase, and
phi29 DNA Polymerase) and co-developed with our stakeholders. These
projects span across various applications, including drug
innovation, in vitro diagnostics, nutrition and healthcare, food
and beverage, and green energy.
About Matwings
Matwings, founded in 2021 by an elite team from Shanghai Jiao
Tong University, is one of the earliest companies to focus on AI
protein models.
Matwings is dedicated to moving beyond
directed evolution methods to design and engineer functionally
optimized proteins by leveraging a proprietary, pre-trained,
AI-based general protein design platform with 780 million curated
full-length protein sequence data, including nearly 500 million
private data.
This cutting-edge technology platform, AccelProtein™, enables us
to engineer proteins and uncover or de novo design novel proteins
with significantly improved properties, including stability,
activity, affinity, yield, etc.
To date, Matwings has successfully engineered more than 30
proteins either proprietary or co-developed with its stakeholders,
and more than 40 ongoing projects
across various applications in pharmaceutical industries and
synthetic biology industries, e.g. key enzymes and proteins
for CMC, innovative Biologics, synthetic biology and more.
Matwings is actively seeking global
partnerships to jointly develop and commercialize new
products.
Contact Information:
Email: info@matwings.com
Website: https://www.matwings.com/en/
Tel: +86 158 2106 5410
Paper Link:
https://www.science.org/doi/10.1126/sciadv.adr2641
View original
content:https://www.prnewswire.com/news-releases/matwings-technology-raised-series-a-funding-of-tens-of-millions-usd-to-redefine-protein-design-302339150.html
SOURCE Matwings Technology